Case Report

Dermatology and Therapy

, Volume 4, Issue 1, pp 131-135

First online:

Open Access This content is freely available online to anyone, anywhere at any time.

Recurrent In Situ Melanoma Successfully Treated with Ingenol Mebutate

  • Marion MansuyAffiliated withDepartment of Dermatology, Skin Cancer Centre, CHU du Sart Tilman, University de Liège
  • , Nazli Nikkels-TassoudjiAffiliated withDepartment of Dermatology, Skin Cancer Centre, CHU du Sart Tilman, University de Liège
  • , Jorge E. ArreseAffiliated withDepartment of Pathology, Skin Cancer Centre, CHU du Sart Tilman, University de Liège
  • , Andree RoriveAffiliated withDepartment of Oncology, Skin Cancer Centre, CHU du Sart Tilman, University de Liège
  • , Arjen F. NikkelsAffiliated withDepartment of Dermatology, Skin Cancer Centre, CHU du Sart Tilman, University de Liège Email author 

Abstract

Background

Treatment options for melanoma in situ (MIS) include imiquimod, radiation therapy, cryotherapy, excisional and Mohs surgery. Ingenol mebutate is a new topical treatment option recognized for actinic keratosis. Although in vitro effectiveness has been demonstrated on melanoma cell lines, its therapeutic potential for in vivo melanomas is unknown.

Case Report

In 2011, a 91-year-old woman presented a thick melanoma of her cheek. The lateral sections revealed persisting in situ melanoma, which were again excised. She presented for follow-up and a recurrent MIS was evidenced centered on the previous scar. She refused further surgery and ingenol mebutate (0.015% gel) was administered on three consecutive days. One month later, a complete clinical resolution was observed. Histology and immunohistology revealed no residual MIS.

Conclusion

In this patient, ingenol mebutate was successful and well-tolerated as a topical, alternative therapy for MIS after failure of other treatment options.

Keywords

Alternative therapy Dermatology In situ melanoma Ingenol mebutate Melanoma treatment Topical treatment